Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study

PLoS One. 2015 Apr 24;10(4):e0125069. doi: 10.1371/journal.pone.0125069. eCollection 2015.

Abstract

Background: Formation of compact and poorly lysable clots has been reported in thromboembolic disorders. Little is known about clot properties in bleeding disorders.

Objectives: We hypothesized that more permeable and lysis-sensitive fibrin clots can be detected in women with heavy menstrual bleeding (HMB).

Methods: We studied 52 women with HMB of unknown cause and 52 age-matched control women. Plasma clot permeability (Ks), turbidity and efficiency of fibrinolysis, together with coagulation factors, fibrinolysis proteins, and platelet aggregation were measured.

Results: Women with HMB formed looser plasma fibrin clots (+16% [95%CI 7-18%] Ks) that displayed lower maximum absorbancy (-7% [95%CI -9 - -1%] ΔAbsmax), and shorter clot lysis time (-17% [95%CI -23 - -11%] CLT). The HMB patients and controls did not differ with regard to coagulation factors, fibrinogen, von Willebrand antigen, thrombin generation markers and the proportion of subjects with defective platelet aggregation. The patients had lower platelet count (-12% [95%CI -19 - -2%]), tissue plasminogen activator antigen (-39% [95%CI -41 - -29%] tPA:Ag), and plasminogen activator inhibitor-1 antigen (-28% [95%CI -38 - -18%] PAI-1:Ag) compared with the controls. Multiple regression analysis upon adjustment for age, body mass index, glucose, and fibrinogen showed that decreased tPA:Ag and shortened CLT were the independent predictors of HMB.

Conclusions: Increased clot permeability and susceptibility to fibrinolysis are associated with HMB, suggesting that altered plasma fibrin clot properties might contribute to bleeding disorders of unknown origin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood Coagulation / physiology*
  • Blood Coagulation Tests / methods
  • Body Mass Index
  • Case-Control Studies
  • Female
  • Fibrin / metabolism
  • Fibrin Clot Lysis Time / methods
  • Fibrinogen / metabolism
  • Fibrinolysis / physiology*
  • Glucose / metabolism
  • Humans
  • Menorrhagia / metabolism
  • Menorrhagia / physiopathology*
  • Middle Aged
  • Permeability
  • Plasma / metabolism
  • Plasma / physiology*
  • Plasminogen Activator Inhibitor 1 / metabolism
  • Platelet Function Tests / methods
  • Thrombin / metabolism
  • Tissue Plasminogen Activator / metabolism

Substances

  • Plasminogen Activator Inhibitor 1
  • Fibrin
  • Fibrinogen
  • Thrombin
  • Tissue Plasminogen Activator
  • Glucose

Grants and funding

The university (grant no. K/ZDS/002936) supported the study. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.